In a significant step forward for cancer immunotherapy, researchers at the Massachusetts Institute of Technology (MIT) and Harvard Medical School successfully designed a novel type of CAR-NK cell therapy that can bypass the human immune system while attacking cancer cells with higher precision and safety. 

The discovery, published in Nature Communications, could be a watershed moment in the search for "off-the-shelf" cell therapies—ready-made treatments that can be provided soon after diagnosis, rather than existing CAR-T therapies that require weeks to manufacture. 

"This allows us to engineer CAR-NK cells in a single step while avoiding rejection by host T cells and other immune cells." Prof. Jianzhu Chen, a senior author of the study from MIT's Koch Institute for Integrative Cancer Research, added that they kill cancer cells more effectively and safely. 

Conventional immunotherapies, such as CAR-T treatment, have altered how doctors treat certain blood malignancies, including lymphoma and leukaemia. However, these treatments rely on changing a patient's own immune cells, which is a time-consuming and expensive procedure that is not always successful. 

In contrast, natural killer (NK) cells are a component of the body's innate immune system. They have the innate ability to recognise and destroy cancerous or virus-infected cells without prior exposure. Engineering these NK cells with a Chimeric Antigen Receptor (CAR) makes them even more effective at attacking cancer cells. 

Is A Safer, Faster Alternative to Personalised Cancer Immunotherapy on the Cards?

The key barrier has been immunological rejection. When NK cells are obtained from a donor rather than a patient, the recipient's immune system frequently recognises them as foreign and eliminates them before they can combat the tumour. The current study explicitly addresses this issue. 

The MIT-Harvard team developed a one-step genetic alteration to let donor-derived NK cells hide from the patient's immune system. They used a small interfering RNA (siRNA) sequence to silence genes that make HLA class 1 proteins, which are molecules that alert T cells to foreign cells. 

In addition, the scientists added two other genes—PD-L1 and HLA-E—that improve NK cells' cancer-killing powers. All of these genetic components were carried on a single DNA construct, making the process faster and more straightforward. The end result was a new breed of CAR-NK cells that live longer and act better against cancer. 

In mouse models with humanised immune systems, the modified cells lasted at least three weeks and nearly cleared lymphomas. In contrast, normal NK cells were rapidly killed, allowing the malignancy to spread. 

The research team, which included Dr Rizwan Romee of Harvard Medical School and the Dana-Farber Cancer Institute, intends to conduct clinical trials to determine the therapy's safety and efficacy in humans. Early research reveals potential applications beyond oncology, such as in autoimmune illnesses like lupus, in which the immune system erroneously targets healthy organs. 

Importantly, these modified NK cells exhibited fewer inflammatory side effects, such as cytokine release syndrome, which is a common danger in immunotherapy. If proven in human research, CAR-NK cell therapy could be a safer and more scalable alternative to CAR-T therapies. 

While the results are intriguing, experts stress that clinical confirmation will be critical. "Off-the-shelf" treatments have the potential to democratise access to sophisticated cancer treatment, but large-scale production and safety monitoring remain big challenges. 

Nonetheless, this discovery highlights a paradigm shift: cancer immunotherapy is going from personalisation to universality – therapies that are faster to create, easier to transport, and safer to use.